According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...

Dupixent achieved over €13 billion in sales, growing 16% in Q4, with strong performance across geographies and indications.

Takeda had hoped that Eohilia would be the first-ever treatment for EoE, but that crown was snatched by Sanofi and Regeneron’s injectable antibody Dupixent (dupilumab), which was approved for ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

Solid sales of Dupixent (approved for use in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis and eosinophilic esophagitis) have fueled the top line for ...

Eosinophilic esophagitis (EoE) is a chronic (long-term) condition affecting the esophagus, the tube that carries food and liquids from the mouth to the stomach. EoE causes symptoms like difficulty ...

Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025Paris, January 30, 2025Q4: ...

Clinicians should be aware of the latest developments in the diagnosis and management of eosinophilic esophagitis (EoE), including new biologics approved for treatment and the elimination of ...